There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioventus (BVS – Research Report) and Palatin Technologies (PTN – Research Report) with bullish sentiments.
Bioventus (BVS)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Bioventus today. The company’s shares closed last Tuesday at $5.33, close to its 52-week high of $5.52.
According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of
Currently, the analyst consensus on Bioventus is a Moderate Buy with an average price target of $7.00, implying a 33.8% upside from current levels. In a report issued on December 7, Canaccord Genuity also upgraded the stock to Buy with a $7.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Palatin Technologies (PTN)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Palatin Technologies today and set a price target of $70.00. The company’s shares closed last Tuesday at $2.42.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $60.00, implying a 2369.1% upside from current levels. In a report issued on December 18, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BVS:
- Bioventus Names Robert Claypoole as President and Chief Executive Officer
- Bioventus upgraded to Buy from Hold at Canaccord
- Bioventus agrees to nationwide contact with Aetna Medicare Advantage plans
- Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
- Bioventus sees FY23 EPS (12c)-(9c)
